The practical implication is that classic drug-interaction reasoning built around liver enzymes usually does not transfer, and that renal impairment matters more than hepatic impairment for many of these compounds
By riffing on a shared guilty pleasure, HUM delivers a light-hearted reminder that convenience doesn't have to come at the cost of health
Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease
Moreover, in subgroup analyses of the controls, tirzepatide did not increase the risks of any of these cancers compared to placebo, insulin, or GLP-1RA (Table 3)
Clinical trials test 0.16 to 4.5 mg subcutaneously once weekly (Lau 2021, Lancet)
doi: 10.1073/pnas.1018359108 183 VanderauweraS.VandenbrouckeK.InzA.van de CotteB.MhlenbockP.de RyckeR.et al